Podcasts about Instinct

This week on Mel & Floyd: Mel is back in the studio!; Kennedy Center tickets available; And other random topics. The post So Much For the Motherly Instinct appeared first on WORT-FM 89.9.

Copyright 2025 A1R Psychic Radio All rights reserved.

Instinct got you through the wilderness, but it won't get you into the Promised Land. In this episode, Jon Chasteen unpacks the critical shift every ReLeader must make: from leading by instinct to leading with intention. Jon shares his personal wake-up call, realizing that frustration with systems, staff, or culture often pointed back to his own leadership failures. Drawing from Joshua's transition moment (“When the manna stopped, Israel didn't panic; they planted”), he explores what it looks like to stop reacting to yesterday's problems and start designing tomorrow's future. Through three practical shifts, Jon shows how ReLeaders can move from survival to strategy:1. Stop Managing Around People — Start Leading Through Culture2. Stop Doing It All — Start Developing Others3. Stop Avoiding Hard Conversations — Start Restoring Healthy AccountabilityWhether you're inheriting a ministry, rebuilding after a crisis, or simply ready to grow beyond maintenance mode, this episode will help you trade instinctual reactions for intentional rhythms that build a healthy, lasting culture.

How do you know what you know? Most of us have been confusing three fundamentally different forms of knowing our entire lives: instinct (the body's survival mechanism), intellect (the mind's analytical tool), and intuition (direct knowing that bypasses thought). Understanding the difference isn't just philosophical, it has immediate implications for every decision you make, from choosing a career path to knowing when to trust someone. On this week's episode of Musings From The Mount, Diana Lang joins the conversation and begins the discussions with an exploration about instinct, that primal gut-level response designed to keep us alive in the face of immediate physical danger and one problem becomes immediately apparent, our instincts haven't evolved as fast as our environment. Our bodies trigger the same fight-or-flight response for a difficult conversation that it would for a predator, which can then lead to chronic stress and reactive decisions. Learning when instinct serves you versus when it hijacks you has become an essential tool for navigating modern life without being ruled by ancient survival programming. We also examine the intellect, a powerful but limited tool. It can analyze, categorize, and problem-solve brilliantly, but it can only rearrange information it already has. The thinking mind is like a computer working with existing data; it cannot access anything genuinely new, so we explore how intellect can itself become a defense mechanism, keeping us in our heads to avoid feeling what is actually happening in our bodies or hearts. This is why breakthrough insights never come from more thinking, they arrive through intuition. This episode offers practical ways to recognize real intuition: it has a quality of quiet certainty, doesn't require justification or mental gymnastics, and often surprises the thinking mind with information it couldn't have logically derived. Intuition is framed as "a download of complete knowing" that arrives whole rather than being built piece by piece and we discuss the key challenge? You can't hear intuition's whisper when you're constantly in motion or consumed by mental chatter. This is an invitation to examine your own decision-making and discover which form of knowing you're actually using and whether it's the right one for the situation at hand. Meditation Mount and HeartLight Productions are pleased to present Musings from the Mount – a weekly podcast with host Joseph Carenza and guests in conversation exploring a range of topics drawn from the Ageless Wisdom teachings. New episodes every Monday. If you enjoy this podcast, please consider donating at MeditationMount.org

Highlights include: Tatum Paxley defeating Jacy Jayne for the NXT Women's Championship. Blake Monroe capturing the NXT North American Women's Championship and more! #wwe #wwenxt #halloweenhavoc #wrestling ---- THIS PODCAST IS SPONSORED ALSO BY MOMENTOUS Go to livemomentous.com, and use promo code INSTINCT for up to 35% off your first subscription order ----CONNECT WITH DENISE SALCEDO ON SOCIAL MEDIA! Tik Tok: https://www.youtube.com/denisesalcedo Twitter: https://twitter.com/_denisesalcedo Instagram: https://www.instagram.com/_denisesalcedo/ Facebook: https://www.facebook.com/denisesalcedovideos Patreon: https://www.patreon.com/c/denisesalcedo Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

1.Dave Shtorn - Celestial (Original Mix) 2.Anton Borin (RU) - The Gate Is You (Original Mix) 3.Andrés Moris - Rust (Sam Sick, Antonio Farhy Remix) 4.Juan Deminicis - Dmt (Original Mix) 5.Indigo Man - Chasing Dreams (Original Mix) 6.Katy Kvint - Essence (goodkidmadcity & Maxi Solo Remix) 7.Al Park - Steel Horizons (Original Mix) 8.BRIAN DE SANTIS - Adamantium (Auseeb Remix) 9.Gaspar Aguilera, Manu Pavez - Reinventado (Original Mix) 10.Seyah - Serenity (Original Mix) 11.Perc Capsule - Fluid Moves (Original Mix) 12.Luciano Vaninetti - Sothis (Original Mix)

'I think the only thing I can rely on is my intuition and instinct,' says this week's house guest Irishman Shayne Brady. A recurring guest on BBC Interior Design Masters (they can't get enough of him and who can blame them), Shayne has recently consciously uncoupled from Brady Williams, the studio he set up with his former business partner Emily over 13 years ago (they still talk most days). He has taken his commercial clients, including restaurant supremo Jeremy King, into the new studio. Among his many projects is the soon to reopen Simpson's in the Strand. Shayne had me giggling most of the afternoon – loved my time with him. Tune in for more.

Copyright 2025 A1R Psychic Radio All rights reserved.

For The Other Side NDE Videos Visit ▶️ youtube.com/@TheOtherSideNDEYT Purchase our book on Amazon

When writer-director Bryan Poyser decided to make a feature over winter break—with no finished script and a team of students—he had no idea it would premiere at Tribeca Film Festival.In this episode of In the Room, host John Williams sits down with Poyser and actors Heather Kafka (The Leftovers, Friday Night Lights) and Justin Arnold (Spike Jonze's Scenes from the Suburbs) to unpack how Leads came to life through collaboration, improvisation, and creative trust.They discuss:Building a feature film without a scriptBalancing creative ambition with real life and financial limitsThe power of collaboration between directors, actors, and studentsFinding purpose and joy in the process—not just the resultAn inspiring, candid conversation about risk, artistic integrity, and rediscovering love for the craft.

IGN Daily Update brings you the latest and most popular news stories to audio platforms. Be sure to check out IGN.com for more details on the news and our latest coverage on games, movies, tv, science, and tech throughout the day! Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode explores Friedrich Nietzsche's philosophy on how to live a life worthy of eternity. It delves into Nietzsche's concept of eternal recurrence, where one's life would have to be lived over and over again, and asks if such a life would be fulfilling and self-justifying.00:00 Introduction: Measuring a Good Life03:30 Eternal Recurrence: Thought Experiment or Truth?08:30 Nietzsche's Moment of Affirmation13:00 Instinct vs. Reason: Nietzsche's Perspective17:00 The Singular Vision: Striving for Greatness21:15 Understanding the Higher Self22:00 Defining Yourself by Your Best Moments22:40 The Importance of Mastering a Craft26:45 The Metaphor of Dance in Life34:35 Nietzsche's Life Advice-----Sponsors:⁠⁠⁠⁠- ⁠⁠Austin AI Lab⁠⁠⁠⁠⁠⁠- ⁠⁠⁠⁠⁠GainsInBulk.com/ben⁠⁠⁠⁠ ⁠⁠⁠⁠⁠ - Use code Ben for 20% off instantized creatine and more⁠⁠⁠⁠- ⁠⁠⁠⁠⁠Speechify.com/ben⁠⁠⁠⁠⁠⁠⁠⁠⁠ - Use code Ben for 15% off Speechify premium⁠⁠⁠⁠- ⁠⁠⁠⁠⁠Founders Podcast⁠⁠⁠⁠⁠----Stay In Touch- Sign up for the newsletter at ⁠⁠⁠⁠⁠takeoverpod.com⁠⁠⁠⁠⁠- Twitter/X - ⁠⁠⁠⁠⁠@BenWilsonTweets⁠⁠⁠⁠⁠- Instagram - ⁠⁠⁠⁠⁠@HTTOTW

First Time?Start Here: https://bit.ly/MarinersconnectcardCan we pray for you? https://bit.ly/MarinersPrayerOnlineYou can find information for all our Mariners congregations, watch more videos, and learn more about us and our ministries on our website https://bit.ly/MarinersChurchSite. Support the ministry and help us reach people worldwide: https://bit.ly/MarinersGiveFIND US ON SOCIAL MEDIA• Facebook: https://www.facebook.com/marinerschurch• TikTok: https://www.tiktok.com/@marinerschurch• Twitter: https://twitter.com/marinerschurch• Instagram: https://www.instagram.com/marinerschurch

Fluent Fiction - Norwegian: Storm Alert: A Thrilling Tale of Instinct and Caution Find the full episode transcript, vocabulary words, and more:fluentfiction.com/no/episode/2025-10-16-22-34-02-no Story Transcript:No: Vinden ulte utenfor den lille politistasjonen, som et rovdyr på jakt.En: The wind howled outside the small police station, like a predator on the hunt.No: Den lille fiskerlandsbyen lå innhyllet i stormens klør, og ute på havet hadde kaoset nettopp funnet sted.En: The small fishing village lay shrouded in the storm's claws, and out at sea chaos had just occurred.No: Sindre sto ved vinduet, så bortover det skummende havet.En: Sindre stood by the window, looking out over the foaming sea.No: Anniken satt på en benk ved siden av, hennes øyne fulle av bekymring.En: Anniken sat on a bench beside him, her eyes full of concern.No: "Vi må fortelle dem om skipet," sa Sindre, og snudde seg mot Anniken.En: "We need to tell them about the ship," said Sindre, turning towards Anniken.No: "De kan være i fare.En: "They could be in danger."No: "Anniken nikket, men så seg rundt i rommet.En: Anniken nodded but looked around the room.No: "Vi er trygge her nå.En: "We're safe here now.No: Stormen er sterk.En: The storm is strong.No: Hva kan vi gjøre?En: What can we do?"No: " Hennes stemme var rolig og stødende.En: Her voice was calm and steady.No: Politistasjonen var et enkelt bygg.En: The police station was a simple building.No: Gamle plakater prydet veggene, bilder av fiskebåter og lokale helter fra fortiden.En: Old posters adorned the walls, pictures of fishing boats and local heroes from the past.No: I dette lille rommet var det knapt plass til håp i stormen.En: In this small room, there was hardly room for hope in the storm.No: Regnet pisket mot vinduet, og lynet lyste opp nattehimmelen.En: The rain lashed against the window, and lightning lit up the night sky.No: Sindre var bekymret.En: Sindre was worried.No: Skipet de hadde sett, hadde gått ned raskt.En: The ship they had seen had gone down quickly.No: Det var noe merkelig med det, noe uforklarlig.En: There was something strange about it, something inexplicable.No: "Vi må finne en måte å kontakte kystvakten på," presset han.En: "We need to find a way to contact the coast guard," he urged.No: Anniken så seg rundt og sukket.En: Anniken looked around and sighed.No: "Radioen virker ikke, stormen blokkerer alt.En: "The radio isn't working; the storm is blocking everything.No: Kanskje det beste er å vente?En: Maybe the best thing is to wait?"No: "Sindre ignorerte hennes tvil.En: Sindre ignored her doubts.No: "Kanskje det er noe vi kan gjøre," sa han bestemt.En: "Maybe there's something we can do," he said determinedly.No: "Hvis vi bare kan få radioen til å fungere.En: "If we can just get the radio to work."No: "Anniken så på ham og kunne ikke la være å smile svakt.En: Anniken looked at him and couldn't help but smile faintly.No: Hun kjente hans stahet altfor godt.En: She knew his stubbornness all too well.No: "Greit," sa hun, "la oss prøve.En: "Alright," she said, "let's try."No: "De beveget seg mot radioen som sto på disken.En: They moved towards the radio that stood on the counter.No: Sindre trykket på knapper, mens Anniken justerte antennen.En: Sindre pressed buttons while Anniken adjusted the antenna.No: De kjempet mot teknologien og stormen.En: They battled against technology and the storm.No: Til slutt, akkurat da stormen virket å trekke pusten, hørtes en svak stemme fra radioen.En: Finally, just as the storm seemed to catch its breath, a faint voice was heard from the radio.No: Kystvakten!En: The coast guard!No: Sindre grep mikrofonen og meldte om skipet i nød.En: Sindre grabbed the microphone and reported the ship in distress.No: Stormen brølte igjen, men denne gangen hadde de en alliert.En: The storm roared again, but this time they had an ally.No: Kystvakten lovte å sende hjelp straks været tillot det.En: The coast guard promised to send help as soon as the weather allowed it.No: Etter timevis av uro kom endelig morgenlyset, da hadde kystvakten ankommet.En: After hours of turmoil, the morning light finally came, by then the coast guard had arrived.No: De rapporterte tilbake at skipet hadde blitt brukt til ulovlige aktiviteter, akkurat som Sindre hadde fryktet.En: They reported back that the ship had been used for illegal activities, just as Sindre had feared.No: Anniken så på Sindre med nye øyne.En: Anniken looked at Sindre with new eyes.No: "Dine instinkter var riktige," innrømmet hun.En: "Your instincts were right," she admitted.No: "Jeg antar jeg kan lære å være litt mer eventyrlysten.En: "I guess I can learn to be a bit more adventurous."No: "Sindre smilte tilbake, og innså verdien av forsiktighet.En: Sindre smiled back, realizing the value of caution.No: "Og jeg kan lære å være litt mer forsiktig," svarte han.En: "And I can learn to be a bit more careful," he replied.No: Polistastasjonsdøren slang igjen, og stormen begynte å dø ut.En: The police station door slammed shut, and the storm began to subside.No: Utenfor viste landsbyen tegn på livet igjen.En: Outside, the village showed signs of life again.No: Med skuldrene lettet, men øynene åpne for det nye, visste Sindre og Anniken at de hadde overkommet mer enn bare stormen.En: With lighter shoulders but eyes open to the new, Sindre and Anniken knew they had overcome more than just the storm.No: De hadde funnet balansen mellom eventyrlyst og fornuft.En: They had found the balance between adventure and prudence. Vocabulary Words:howled: ultepredator: rovdyrshrouded: innhylletchaos: kaosetfoaming: skummendeconcern: bekymringadorned: prydetlashed: pisketinexplicable: uforklarligurged: pressetsighed: sukketdoubts: tvilstubbornness: stahetfaintly: svaktbattled: kjempetally: alliertturmoil: uroinstincts: instinkteradventurous: eventyrlystencaution: forsiktighetsubside: dø utprudence: fornuftconcerned: bekymretstealthily: luretfrantically: febrilskuneasy: ubehageligplunge: stuperevelation: avsløringreassured: beroligetdefiantly: trodsig

Nearly 1 in 3 American adults admit they're still afraid of the dark — and surprisingly, men report that fear more often than women. In this fascinating and surprisingly relatable episode, the hosts explore why that fear exists and why it might actually be a good thing. From ancient survival instincts and the primal role of men as protectors to modern security habits and archaeological evidence of early human danger, this episode dives into the biology, anthropology, and psychology of why the dark still unnerves us. Featuring listener texts, real science, and a dash of humor, it's a journey from cave fires to motion-sensor lights — and what the darkness says about who we are.

We're talking strikers this week — the ones who live for goals, tap-ins, screamers, and everything in between. Do the best No. 9s rely on stats and positioning, or is it all about instinct and feel? We get into it.Plus, we're checking out some of the newest faces leading the line this season — Gyökeres, Ékitiké, Isak, Šeško, João Pedro — who's ready to explode, and who still needs time? And of course, we're throwing out our picks for the next breakout striker in the league. Could be a bold shout, could be bang on. Tune in and find out._____________________________________________________________Featuring Matthew, Craig, Clive & Markus.Visuals by Clive Follow Eightseven on: https://www.facebook.com/eightseven.uk/ https://www.instagram.com/eightseven.uk/ https://twitter.com/eightsevenuk/

Clement Manyathela speaks to Keshnie Mathi, CEO of The Wellness Specialist who shares insights on what intuition is and how to distinguish between intuition and gut feelings that stem from fear and trauma. The Clement Manyathela Show is broadcast on 702, a Johannesburg based talk radio station, weekdays from 09:00 to 12:00 (SA Time). Clement Manyathela starts his show each weekday on 702 at 9 am taking your calls and voice notes on his Open Line. In the second hour of his show, he unpacks, explains, and makes sense of the news of the day. Clement has several features in his third hour from 11 am that provide you with information to help and guide you through your daily life. As your morning friend, he tackles the serious as well as the light-hearted, on your behalf. Thank you for listening to a podcast from The Clement Manyathela Show. Listen live on Primedia+ weekdays from 09:00 and 12:00 (SA Time) to The Clement Manyathela Show broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/XijPLtJ or find all the catch-up podcasts here https://buff.ly/p0gWuPE Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

This week, we trace two seismic shifts redefining both the AI race and the global economy. OpenAI–AMD Alliance marks a structural realignment in the AI hardware landscape. The multi-year partnership grants OpenAI access to up to 6 GW of AMD's next-generation Instinct accelerators—a move that diversifies its compute base beyond NVIDIA and positions AMD as a credible second supplier in the frontier-model era. The deal, which could add tens of billions in market value, signals a future where model developers and chipmakers are financially intertwined to secure compute sovereignty. U.S.–China Trade Confrontation re-enters a critical phase as Washington moves to impose 100 percent tariffs on nearly all Chinese imports, citing Beijing's rare-earth export restrictions as a strategic threat. The escalation threatens to fragment technology supply chains, drive inflationary pressure in the U.S., and accelerate the formation of rival industrial blocs—America's “friend-shoring” network versus China's Belt-and-Road manufacturing orbit. Together, these developments expose a world where AI capacity, economic power, and geopolitical control are converging into the same equation—and where nations, companies, and investors must decide which ecosystem they belong to. Powered by Firstory Hosting

Send us a textThe Four Tendencies in Birth: How Knowing Yourself Shapes Your ExperienceIn this episode of The Ultimate Birth Partner Podcast, I explore how Gretchen Rubin's Four Tendencies framework can help women, partners, and birth professionals better understand how we respond to expectations — and why that matters so much in pregnancy and birth.I share real-life examples of how each Tendency (Upholder, Questioner, Obliger, Rebel) might prepare for birth, how they may respond in the moment, and the unique challenges or strengths they bring into the birth room.You'll hear:✨ Why self-awareness is one of the most powerful tools you can take into labour✨ How partners can better support by recognising their own style and their loved one's needs✨ Why birth professionals and doulas benefit from tailoring their approach depending on the woman or family they're working with✨ What to do if you don't know your care provider's Tendency — and how to get your point across clearly in the moment✨ How to express your own Tendency in your Birth Manifesto® so your values, priorities, and boundaries are unmistakably clearThis episode is full of stories, practical strategies, and even scripts you can use to explain yourself to others, helping you strengthen your inner compass and stay aligned with what matters most.Resources & Links:Learn more about creating your Birth Manifesto® in my Discover Your North Star course - https://payhip.com/b/8PSYiGretchen Rubins The Four Tendencies Quiz - https://gretchenrubin.com/quiz/the-four-tendencies-quiz/If you enjoyed this episode, please share it with a friend or leave a review — it makes such a differenceIf you love the podcast and would like to support it, then please use the link to 'buy me a coffee' - https://bmc.link/sallyannberesfordIf you would like to buy a copy of either of the books that accompany this podcast please go to your online bookseller or visit Amazon:-Labour of Love - The Ultimate Guide to Being a Birth Partner - click here:-https://bit.ly/LabourofloveThe Art of Giving Birth - Five Key Physiological Principles - https://amzn.to/3EGh9dfPregnancy Journal for 'The Art of Giving Birth' - Black and White version https://amzn.to/3CvJXmOPregnancy Journal for 'The Art of Giving Birth'- Colour version https://amzn.to/3GknbPFYou can find all my classes and courses on my website - www.sallyannberesford.co.uk Follow me on Instagram @theultimatebirthpartner Book a 1-2-1 session with Sallyann - https://linktr.ee/SallyannBeresford Please remember that the information shared with you in this episode is solely based on my own personal experiences as a doula and the private opinions of my guests, based on their own experiences. Any recommendations made may not be suitable for ...

Copyright 2025 A1R Psychic Radio All rights reserved.

In this episode James P. Dowling talks us through the unlikely friendship between physicist Wolfgang Pauli and psychologist Carl Jung. Their dialogue on quantum mechanics and archetypes pulled science and myth into the same room, forcing each to reckon with the other's language. Out of their exchanges came visions of atoms haunted by the unconscious, and shadows that reached into equations. We follow their conversation to ask what happens when reason and dream try to share the same desk.PATREON https://www.patreon.com/c/demystifysciPARADIGM DRIFThttps://demystifysci.com/paradigm-drift-showHOMEBREW MUSIC - Check out our new album!Hard Copies (Vinyl): FREE SHIPPING https://demystifysci-shop.fourthwall.com/products/vinyl-lp-secretary-of-nature-everything-is-so-good-hereStreaming:https://secretaryofnature.bandcamp.com/album/everything-is-so-good-hereJames' website: https://jungtoliveby.com/00:00 Go! 00:08:00 The Trickster Archetype and Personal Development00:12:00 Intuition and Rationality in Model Making00:16:00 Consequences of the Enlightenment and Modernity00:20:00 Historical Lessons from the French Revolution00:22:23 Discussion of Instinct vs. Rationality in Human Behavior00:24:12 The Role of Dopamine in Human Decision Making00:26:18 The Impact of Abandoning Symbolism in Modernity00:29:00 Motivation in Physics and the Pursuit of Glory00:33:26 The Dichotomy between Science and the Human Experience00:39:11 Integrating Jungian Concepts with Biology00:44:58 Discussing Jung's Word Association Test and Complexes00:50:12 Understanding Affect, Emotion, and Archetypes00:57:32 Jung's Methodology and Interpretation of Complexes01:05:12 Approaching Jungian Concepts in Personal Development01:07:33 The Quest for Identity and Self-Reflection01:09:37 Generational Differences in Self-Concept01:16:52 Life Stages and the Search for Meaning01:19:10 The Duality of Growth and Identity01:25:09 The Healing Power of Creativity01:28:31 Creative Participation as a Human Experience01:32:06 Internet's Dual Role in Creativity01:36:23 Understanding Creativity and Instinct01:39:51 Renaissance vs. Revolution in Institutions01:41:53 Engaging with the Unconscious Mind01:46:47 Shifting Perspectives on Artistic Process01:48:52 Discussion on Competing Teams in Science01:52:34 The Tradition and Lineage in Science01:56:12 Creativity and Glory in Scientific Pursuits02:04:36 The Nature of Truth and Scientific Frameworks02:09:43 Cultural Narratives in Science and AI Development02:10:29 Exploration of Myth and Reality02:12:06 Darwin's Legacy and Evolutionary Theory02:16:52 Archetypes and Scientific Paradigms02:19:14 The Role of Mathematics in Physics02:23:39 Understanding the Limits of Rational Inquiry02:27:24 Simulation Theory and Metaphysical Speculation02:32:05 The Interplay of Mathematics and Experience02:33:00 Exploration of Human Psyche and Evolutionary Perspectives02:36:12 Jung's Insights on Individual Calling and Collective Responsibility02:39:01 Invitation to Further Exploration and Collaborative Learning#jungianpsychology, #quantummechanics, #carljung, #archetypes, #depthpsychology, #unconsciousmind, #psychoanalysis, #philosophypodcast , #sciencepodcast, #longformpodcastMERCH: Rock some DemystifySci gear : https://demystifysci-shop.fourthwall.com/AMAZON: Do your shopping through this link: https://amzn.to/3YyoT98DONATE: https://bit.ly/3wkPqaDSUBSTACK: https://substack.com/@UCqV4_7i9h1_V7hY48eZZSLw@demystifysci RSS: https://anchor.fm/s/2be66934/podcast/rssMAILING LIST: https://bit.ly/3v3kz2S SOCIAL: - Discord: https://discord.gg/MJzKT8CQub- Facebook: https://www.facebook.com/groups/DemystifySci- Instagram: https://www.instagram.com/DemystifySci/- Twitter: https://twitter.com/DemystifySciMUSIC: -Shilo Delay: https://g.co/kgs/oty671

This week on Diabetes Connections.. Medtronic is making some big moves.. from new sensors, to spinning off the diabetes division.  Dr. Jen McVean, medical affairs director at Medtronic's diabetes business. Dr. McVean lives with type 1 and has a real passion for better access and better outcomes using technology. We talk about their latest real-world studies, questions doctors ask about these systems, the new sensors that are now available and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our last episode with Medtronic about their upcoming products and partnerships here (from May 2025) More about Medtronic's new Instinct sensor here More from Medtronic about the news here Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Arsenal are back on top of the league and the vibes are immaculate. Johnny and Matt break down a smooth, drama-free win over West Ham — exactly the kind of performance Arsenal have been missing in recent seasons. We get into:

The Goal Should Be... Unobstructed Self-Expression What we see in Schools/Grassroots 1. Preparation for the real world or to ignore yourself 2. Natural insticts gone by age 7 3. Contributing mechanisms to look 4. Mistakes 5. Expression and Emotions 6. What happens at the age of 10

Join us as Pastor Kip Richmond gives us message on how Love is our Instinct at Generation Church. For more information, please visit www.generationchurch.org.

No one knows how long this rally will last — but history shows that the best returns come to those who lean into value, not emotions. Chasing what feels “safe” often leads to buying high and selling low. The real edge comes from staying disciplined when headlines and emotions are screaming the opposite. Here's what we cover in this episode: • Why your brain interprets up-markets and down-markets backwards — and how that instinct can quietly sabotage long-term results. • How price and value diverge during volatility — and why falling prices often mean growing opportunity. • The mindset shift that turns falling markets into opportunity — practical ways to reframe risk so you can act rationally when it matters most. • Lessons from history — what past market cycles can teach us about the link between discipline, patience, and wealth building. As always, thank you for listening, learning, and trusting us with your financial journey. Here's to wise investing, The Iron Gate Global Team

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

Copyright 2025 A1R Psychic Radio All rights reserved.

Tom Vanderzeil aka @passive.kneeling joins us for a chat about our recent collaborations and the music video's he's directed for us for INSTINCT and GODSPEED. We also get into the vibe of a Didi, going too hard at social sports, the musical he created with Kuya Neil, why bands should think about touring asia more, and how to spot manufactured community vs the real thing.Shout outs @passive.kneeling (also check out @content.net.au)https://www.passivekneeling.com/Make sure you grab a ticket to our aus tour in October: https://tnsw.co/tourOur new album GODSPEED is out Nov 28 — pre-order your copy: https://tnsw.co/godspeedpreorder For weekly bonus episodes and to support the pod up to our Patreon — it's only 5 bucks a month, but it's still 5 bucks!: https://patreon.com/whatagreatpunkJoin us all in the TNSW Discord community chat:https://tnsw.co/discordWatch our Comedy Central mockumentary series and TNSW Tonight! on YouTube:https://youtube.com/thesenewsouthwhalesTNSW on Spotify:https://open.spotify.com/artist/0srVTNI2U8J7vytCTprEk4?si=e9ibyNpiT2SDegTnJV_6Qg&dl_branch=1TNSW: @thesenewsouthwhalessJamie: @mossylovesyouTodd: @mrtoddandrewshttps://patreon.com/whatagreatpunkhttps://thesenewsouthwhales.comShout-outs to the Honorary Punks of the Pod:Harry WalkomHugh FlassmanZac Arden BrimsClaireJimi KendallLachy TanDerrotonin69Adjoa SamPatrik Sivák

Disney is preparing to yank Jimmy Kimmel Live! off ABC once his contract expires in May 2026, plotting a full-scale streaming takeover on Disney+ or Hulu — free from FCC broadcast rules. Taylor Swift’s backup dancer Jan Ravnik is making history as the highest-paid first-year pro on Dancing with the Stars, pocketing more than longtime veterans. Meghan Markle is unfazed by Stassi Schroeder’s jabs — because she doesn’t even know who the former Vanderpump Rules star is. Instinct magazine’s Corey Andrew joins Rob with all the dish! Don't forget to vote in today's poll on Twitter at @naughtynicerob or in our Facebook group. See omnystudio.com/listener for privacy information.

My guest today is Barry Diller. Barry is the former CEO of Paramount Pictures, Fox Broadcasting, and the founder of IAC. He has been at the center of every major media transformation over the past five decades, from creating the Movie of the Week format to building the fourth broadcast network to executing 150 internet-era deals. Barry reveals his "creative conflict" philosophy - pushing smart, opinionated people past their endurance point to generate breakthrough ideas. He also shares stories of working alongside media titans like Rupert Murdoch and Bill Gates. We discuss his current portfolio strategy, innovation in media, and how personal struggles can become professional superpowers. Please enjoy my conversation with Barry Diller.  For the full show notes, transcript, and links to mentioned content, check out the episode page ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠⁠⁠ ----- This episode is brought to you by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ramp⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Ramp's mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ramp.com/invest⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to sign up for free and get a $250 welcome bonus. – This episode is brought to you by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ridgeline⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Ridgeline has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Head to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ridgelineapps.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to learn more about the platform. – This episode is brought to you by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ AlphaSense⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. AlphaSense has completely transformed the research process with cutting-edge AI technology and a vast collection of top-tier, reliable business content. Invest Like the Best listeners can get a free trial now at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Alpha-Sense.com/Invest⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and experience firsthand how AlphaSense and Tegus help you make smarter decisions faster. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). Show Notes: (00:00:00) Welcome to Invest Like the Best (00:05:02) Early Career in Entertainment (00:06:33) Defining Moments and Fearlessness (00:09:18) Personal Reflections and Family Impact (00:12:37) The Magic of Interactivity (00:14:44) Creative Conflict and Instinct (00:19:24) Breaking Down Complexities (00:21:35) Innovations in Television (00:23:37) The Fox Network and Murdoch's Gamble (00:29:37) The Value of Money and Motivation (00:30:17) The Leap to Independence (00:32:28) QVC and the Internet Revolution (00:33:37) The AI Opportunist Approach (00:36:55) The Rise of Match.com and Tinder (00:38:57) The MGM Investment and Future of Entertainment (00:41:21) Negotiation Lessons from Lou Wasserman (00:43:47) The Simpsons: From Doubt to Success (00:44:25) The Changing Landscape of Media (00:51:53) The Kindest Thing Anyone Has Ever Done for Barry

Jennifer Aniston and Howard Stern are distancing themselves from ABC after the network’s suspension of Jimmy Kimmel, making it clear their loyalty lies with the late-night host. Meanwhile, the Kardashian empire is bracing for its biggest internal clash yet as Kim Kardashian prepares to launch Skims Beauty in 2026 — a direct shot at Kylie Jenner’s billion-dollar cosmetics empire. And over in Bravo land, Real Housewives of New Jersey stars Teresa Giudice and Melissa Gorga are on their final warning, with producers bluntly telling them to work together on camera or risk being fired. Instinct magazine’s Corey Andrew joins Rob with all the dish! Don't forget to vote in today's poll on Twitter at @naughtynicerob or in our Facebook group.See omnystudio.com/listener for privacy information.

Matthew and Alyce welcome back renowned antique jewellery specialist Michael Singer, Director of Acquisitions at Windsor, New York. Michael shares stories of some remarkable adventures from his decades in the trade including trading a 15th-century manuscript for a Kashmir sapphire, finding a one-of-a-kind Tiffany necklace with ties to the French royal family and bending the rules of an auction...for love! Michael also reflects on the lost buzz of New York's 47th Street, the importance of trusting your instincts, the influence of his father on his career and also shares numerous insider tips such as which antique jewellery he thinks is the most undervalued collectible in America today. www.courtville.ie Get social with Courtville, follow us on Instagram, Facebook, and TikTok This podcast was produced for Courtville by Tape Deck

We start by talking about a C26 athlete that raced without a watch at Ironman Wisconsin and dive into the mentality of being in tune with your body. We get into the psychology of logged workouts and really understanding what's going on from day to day. We talk about why 3 Zones may be all you need to train by. We get into data trends over time and if you're chasing the wrong goals. One of the hardest parts of this sport is recognizing minimal and imperceptive changes in the short term. We talk athlete over-analysis, and why most often don't even know what they're really looking at. We look at why aerobic training works and how making things feel easy might be the most underrated part of training. Topics: Racing without a watch Gauging time by the sun Primal instincts The psychology of logging and reading workouts Nasal breathing as the perfect technology Why most athletes might be better off training with only 3 Zones Going backwards Resisting the over analysis temptations Things that can affect our breathing Warming up the lungs Chasing that labored feeling too much When you're chasing the wrong goals Recognizing small gains or changes Athlete over-analysis Why many athletes don't really understand what they're looking at So many combinations of variables Some of your medium sessions might be your best Making things feel easy The true power of aerobic work Long term system work World Championship Predictions   Mike Tarrolly - mike@c26triathlon.com Robbie Bruce - robbie@c26triathlon.com

Prince Harry’s private tea with King Charles III wasn’t just a father-son thaw — it was fueled by fears over the monarch’s declining health. Mel Owens, the retired NFL linebacker turned Golden Bachelor star, is scrambling to fix his image after controversial comments about dating age limits, now insisting there’s “no age to love.” Britney Spears is navigating fractured family ties nearly three years after her conservatorship ended. Instinct magazine’s Corey Andrew joins Rob with all the dish! Don't forget to vote in today's poll on Twitter at @naughtynicerob or in our Facebook group. See omnystudio.com/listener for privacy information.

✋    Instincts say you're too young, or too old, or too late, or too early. Maybe you should stop listening to that voice…   #KingdomSpeak #Podcast  #Instinct

Be A Better You Annual Challenge Day 253: Spiritual Well-Being And Intuition? Do one thing every day to be a better you! Join us every day in 2025 for a quick challenge that is all about you improving and creating the life you want! https://www.facebook.com/ThrivingSharon Ask your questions and share your wisdom! #beabetteryouannualchallenge #spiritual #intuition #instinct #sixthsense #spiritualwellbeing

Hoda Kotb and Kelly Clarkson’s once-tight friendship has imploded after NBC quietly floated Hoda as a replacement for The Kelly Clarkson Show, leaving Kelly feeling betrayed. Meanwhile, the DWTS ballroom is already in meltdown mode as Hilaria Baldwin “lost it” when paired with veteran pro Gleb Savchenko instead of buzzy newcomer Jan Ravnik, Taylor Swift’s Eras Tour dancer. And in Hollywood, Paris Jackson is threatening to torpedo the $100 million Michael Jackson biopic. Instinct magazine’s Corey Andrew joins Rob with all the dish! Don't forget to vote in today's poll on Twitter at @naughtynicerob or in our Facebook group.See omnystudio.com/listener for privacy information.

In this solo episode, I explore the delicate balance between external writing resources (craft books, courses, workshops) and your internal creative intuition. I'm talking to writers who feel overwhelmed by all the advice out there while trying to maintain their authentic voice.What I'm sharing:Resources and intuition aren't opposites—they're dance partners that should work together. I want you to think of craft books and courses as offerings from other writers' journeys, not commandments you must follow. Creative intuition isn't "winging it"—it's sophisticated intelligence drawing on everything you've experienced.Four gentle practices I've discovered:Learning and Letting Go: Sit with advice before applying it; let your project tell you what it needsInternal Compass Check: Feel whether advice makes your work more alive or less aliveSelective Bibliography: Choose 1-2 craft resources that consistently nourish your creative spiritConversation Practice: Engage with craft advice as dialogue, not gospelWhat I want novel writers to remember:Trust your creative ecosystem—you're already a complete creative being. Create resource boundaries, honor your creative seasons, and remember that your novel is a living thing that grows through collaboration between conscious learning and unconscious knowing.You don't have to choose between being studious and intuitive—you can be a "whole writer" who honors both craft knowledge and creative authenticity.

In this part 2 episode with Alan Altizer, we go deep on the difference in hunting any buck vs. focusing on one buck. We also have an extremley in depth conversation on wind, thermals and how mature bucks use them in ways other deer do not. Other subjects: The difference in mindset between hunting any buck versus targeting one specific mature buck. How tactics shift depending on whether you're hunting for opportunity or for a particular deer. The role of trail cameras — when they help, when they mislead, and why woodsmanship still matters more. Instinct and experience as defining qualities of great hunters. How patience, diligence, and time in the woods separate consistently successful hunters from others. Why repetition (getting reps) killing deer with a bow builds confidence and sharpens execution. The importance of woodsmanship skills (judging distance, reading sign, moving quietly, handling wind and thermals). The difference between being able to kill deer in general vs. consistently killing mature bucks. The value of learning from mistakes and adapting strategies instead of repeating failures. The idea that success in hunting mirrors success in life — dedication, persistence, and growth. Got a question for the show? Submit a listener Q&A form - https://l.linklyhq.com/l/1uMXP Grab some Southern Outdoorsmen merch here - https://l.linklyhq.com/l/1u4aK Join Woodsman Wire - https://l.linklyhq.com/l/1u4aR Use the promo code “southern” for a discount on your OnX Hunt membership here - https://l.linklyhq.com/l/1tyfm Check out Latitude Outdoors for your mobile hunting gear - https://2ly.link/1zVDI Use code TSOP15 for a discount on Mossy Oak - https://linkly.link/2ERb8 Save 10% on your next Vortex Optics order at eurooptic.com using the Promo Code “southern10” - https://2ly.link/1wyYO Use code SOUTHERN20 for a discount on all vortex apparel, including eyewear Use code “SOUTHERN25” for a discount on Houndstooth Game Calls: https://2ly.link/24tFz Have you tagged a deer using something you heard on the show? Submit your listener success story here - Share Your Story Here Come chat with us on our Thursday Hunter Hangouts! Join our patreon - https://l.linklyhq.com/l/1uMXU NOTE: Not all advertisements run on this show are endorsed by The Southern Outdoorsmen Podcast unless an ad is read by one of the hosts.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Fancy setting us a gaming challenge? Get in touch here!In this episode Scott and Matt try and create a physics based horror game. Will the results be horrifying? Well yes, in so many ways...Thanks for listening and please leave us a review and subscribe if you enjoyed it. It really helps us out. Also please get in touch with us at @gamingblendpod or thegamingblenderpod@gmail.com with your ideas for new games and challenges.Keep blending!

In this episode of The Property Profits Real Estate Podcast, host Dave Dubeau sits down with seasoned investor and developer Josh Green of Alchemy Development to explore the art and strategy of building in a changing market. With over a decade of experience in multifamily appraisal, consulting, and development, Josh shares how he's navigating today's shifting real estate landscape through a combination of infill townhome projects, market-driven consulting, and teaching the next generation of developers. From the challenges of raising $4 million for his first flagship build-to-rent project to the realities of land acquisition in a high-interest rate environment, Josh offers candid insight into what it takes to pivot, adapt, and succeed in 2025. He also reveals why he's leaning into land entitlement projects and how his conservative underwriting approach has kept his pipeline strong despite market headwinds. If you're an investor, developer, or someone fascinated by real estate's constant evolution, this conversation is packed with valuable takeaways and practical strategies you can apply right now.     - Get Interviewed on the Show! - ================================== Are you a real estate investor with some 'tales from the trenches' you'd like to share with our audience? Want to get great exposure and be seen as a bonafide real estate pro by your friends? Would you like to inspire other people to take action with real estate investing? Then we'd love to interview you! Find out more and pick the date here: http://daveinterviewsyou.com/

(7:00) TOP 5 SONGS FROM GOD DOES LIKE UGLY(33:00) 5 BURNING QUESTIONS FOR CFB SEASON (1:26:00) NBA DIVISION SERIES: SOUTHEAST DIVISION FINAL SAY: 1:36:36

New Orleans isn't just about beignets and brass bands—it's a test case for how hotels handle unpredictable demand. I spoke with Ken Jacques, GM of Le Meridien New Orleans, which is operated by Stonebridge, about how he's planning for 2026 and what it really takes to run a hotel in a city built on events. Here's what stood out: Hotels can't just copy last year's budget — they're recalibrating daily Events like Mardi Gras, Jazz Fest, and UFC change everything for revenue planning Instinct plays as big a role as spreadsheets when forecasting demand International travel remains a wild card that could shake up results New Orleans is seeing its cleanest, safest stretch in decades—and that's great for business Ken pulls back the curtain on hotel strategy giving me new perspective on how leaders adapt in real time. Special thanks to Actabl: Actabl gives you the power profit. Visit them at Actabl.com. #NoVacancyNews #Hospitality

In this episode of SuperPsyched, host Dr. Adam Dorsay interviews Dr. James Hollis, a renowned Jungian analyst, about finding effective strategies to navigate change and crisis. The conversation delves into the coping mechanisms people often turn to during troubling times and why they are unsustainable in the long run. Dr. Hollis shares insights from his latest book, 'Living Between Worlds: Finding Personal Resilience in Changing Times,' highlighting the importance of looking inward for guidance. They discuss how societal changes impact personal well-being and the necessity of becoming more intimate with oneself. Active imagination, dream analysis, and other self-reflective practices are emphasized as essential tools for personal development and resilience. This episode offers a deep exploration into the unconscious mind and practical steps to harness inner wisdom for facing life's challenges.00:00 Introduction to SuperPsyched00:28 Coping with Change and Crisis01:09 Introducing Dr. James Hollis03:02 The Death of Pan and Cultural Shifts07:34 The Role of Instinct and Adaptation14:35 The Importance of Solitude and Inner Work18:19 Understanding the Self and Ego22:20 Practical Tips for Resilience28:20 The Importance of Dreaming29:13 Understanding Symbolic Language31:56 The Role of Therapy and Self-Discipline34:50 Facing Midlife Challenges42:19 Embracing Curiosity and Overcoming Fear44:18 Active Imagination and Self-Discovery53:42 Concluding Thoughts and ReflectionsHelpful Links:Dr. James HollisLiving Between Worlds: Finding Personal Resilience in Changing Times Book

           In this episode of the Pet Pig Podcast, host Autumn takes a deep dive into one of the most frequent questions she receives from new pig owners: “Why does my pig root so much?” Rooting—whether in the dirt, on furniture, or on you—is one of the most recognizable and instinctual behaviors pigs display. But it's often misunderstood.           Autumn breaks down the five main reasons pigs root: to search for food, to cool off and regulate their temperature, to build nests, to communicate and bond socially, and to explore their world for mental stimulation. She explains how this behavior is not only normal, but essential to a pig's well-being.          Listeners will learn how rooting is tied to survival instincts, and how even pet pigs in loving homes will still feel the strong urge to root daily. Autumn also explores how early weaning can lead to compulsive rooting, especially on people, because piglets who miss out on rooting with their mother try to satisfy those unmet needs later in life—sometimes in ways that become frustrating or even painful for their human families.           Rooting on people may start out as cute, but it can easily become uncomfortable or even aggressive as the pig grows. Autumn discusses how to redirect this behavior early on with safe alternatives like blankets, stuffed animals, digging boxes, puzzle feeders, and outdoor rooting areas. She shares tips on using thrifted materials to build up a pig's rooting “toolbox,” rotating enrichment items to avoid boredom, and creating safe spaces that satisfy your pig's natural drive to dig, nudge, and nest.          This episode is essential listening for anyone who has a pig, is considering getting one, or wants to better understand pig behavior. Rooting isn't a behavioral issue to “fix”—it's a message from your pig's instincts. When we listen to that message and meet our pigs where they are, we can create healthier, safer, and happier environments for them to thrive. Autumn's Links:  Website: https://www.autumnacresminipetpigs.com/ Email: https://stan.store/autumnacresminipetpigs Educational Membership Group: https://stan.store/autumnacresminipetpigs/p/autumn-acres-educational-membership-group Instagram: https://www.instagram.com/autumnacresminipetpigs/ Facebook:  HTTP://Facebook.com/autumnacresminipetpigs Free Community: https://stan.store/autumnacresminipetpigs/p/autumn-acres-free-community YouTube: https://youtube.com/channel/UCGue5Kp5AwOXkReCGPUyImA Stan Store: https://stan.store/autumnacresminipetpigs Newsletter: https://stan.store/autumnacresminipetpigs

Federal prosecutors have shredded Sean “Diddy” Combs’ bid for a new trial, blasting the mogul as the “master of his own freak-offs” in a fiery legal takedown. Meanwhile, Hollywood golden girl Gwyneth Paltrow’s once-gushy friendship with Dakota Johnson has quietly fizzled in the wake of Chris Martin’s split. And in Nashville, country rebel Morgan Wallen is back to thumbing his nose at the industry. Instinct magazine’s Corey Andrew joins Rob with all the dish! Don't forget to vote in today's poll on Twitter at @naughtynicerob or in our Facebook group. See omnystudio.com/listener for privacy information.

In this episode, Adam and Dave start with a lighthearted story about a suspicious liquor store and end up diving into one of the most serious struggles facing men today: restraining our instincts.They reflect on:The challenges of summer routines, distractions, and drifting prayer livesThe importance of order and rhythm in family and spiritual lifeHow our passions can overwhelm us if not properly trainedPractical steps for purifying the memory and avoiding near occasions of sinThe balance between embracing God's gifts and remembering the GiverWhat it means to fight temptation as husbands and fathers, especially in seasons of abstinenceEncouragement from the spiritual masters: why pressure can be good and why we must never assume we're immune from temptationWith humor, honesty, and practical advice, Adam and Dave remind us that peace is the tranquility of order and that holiness requires vigilance, fraternity, and grace.

Prince Harry and Meghan Markle’s much-hyped Netflix “renewal” is more smoke than fire, with insiders insisting the PR spin far outweighs any real payday. Meanwhile, Chris Hemsworth’s 42nd birthday in Ibiza brought out a galaxy of stars — Matt Damon, Rita Ora, Taika Waititi, Liam Hemsworth — but notably left Ben Affleck off the guest list. And back in New York, Pete Davidson’s claims of feeling like an outsider on Saturday Night Live aren’t winning sympathy, with sources saying the cast is tired of him being “more famous for dating than comedy.” Instinct magazine’s Corey Andrew joins Rob with all the dish! Don't forget to vote in today's poll on Twitter at @naughtynicerob or in our Facebook group.See omnystudio.com/listener for privacy information.

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684